Scientists have developed a powerful new gene-editing platform that allows them, for the first time, to systematically test the function of key proteins in mammalian cells. Using the technology, ...
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results